The estimated Net Worth of Fred Broadway is at least $3.01 Millón dollars as of 28 September 2018. Mr. Broadway owns over 90,113 units of HeartBeam Inc stock worth over $258,734 and over the last 11 years he sold BEAT stock worth over $1,698,333. In addition, he makes $1,055,590 as President y BioTel Heart at HeartBeam Inc.
Fred has made over 14 trades of the HeartBeam Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 90,113 units of BEAT stock worth $319,901 on 28 September 2018.
The largest trade he's ever made was exercising 90,113 units of HeartBeam Inc stock on 28 September 2018 worth over $319,901. On average, Fred trades about 8,156 units every 28 days since 2014. As of 28 September 2018 he still owns at least 114,993 units of HeartBeam Inc stock.
You can see the complete history of Mr. Broadway stock trades at the bottom of the page.
Fred Anthony Broadway III serves as President, BioTel Heart of the Company. Mr. Broadway was named President of BioTel Heart in January 2018. In this role, Mr. Broadway has leadership for all sales, marketing, customer service, monitoring, contracting, reimbursement and distribution teams supporting the Healthcare Services business. Mr. Broadway joined us in June 2009 as our Vice President, Marketing, bringing 15 years of progressive leadership experience in sales and marketing, including extensive therapeutic knowledge in Cardiology and Neurology. In September 2012, Mr. Broadway was promoted to Senior Vice President, Marketing, and in January 2013, Mr. Broadway became our Senior Vice President, Sales and Marketing. Prior to joining us, from 2006 to June 2009, Mr. Broadway was Director of Marketing at Bristol Myers Squibb, leading the commercialization launch efforts of a potential new therapy for the treatment of stroke prevention in atrial fibrillation. Earlier in his career, Mr. Broadway was on the marketing team at Pfizer, responsible for developing yearly and long-term strategic plans, brand and portfolio positioning, asset life cycle development, and overseeing commercialization tactics for several leading brands. Mr. Broadway started his career with Sanofi Pharmaceuticals, where he held numerous positions of increasing responsibility including sales, marketing, and eventually leadership positions in both sales and marketing. Mr. Broadway received his undergraduate degree in Zoology from Auburn University.
As the President y BioTel Heart of HeartBeam Inc, the total compensation of Fred Broadway at HeartBeam Inc is $1,055,590. There are 2 executives at HeartBeam Inc getting paid more, with Joseph Capper having the highest compensation of $4,133,160.
Fred Broadway is 50, he's been the President y BioTel Heart of HeartBeam Inc since 2018. There are 15 older and 2 younger executives at HeartBeam Inc. The oldest executive at HeartBeam Inc is Robert Rubin, 74, who is the Independent Director.
Fred's mailing address filed with the SEC is 1000 CEDAR HOLLOW ROAD, , MALVERN, PA, 19355.
Over the last 11 years, insiders at HeartBeam Inc have traded over $23,124,978 worth of HeartBeam Inc stock and bought 31,500 units worth $221,145 . The most active insiders traders include Joseph H Capper, Heather C Getz y Willem Elfrink. On average, HeartBeam Inc executives and independent directors trade stock every 32 days with the average trade being worth of $55,046. The most recent stock trade was executed by Urioste George De on 6 September 2024, trading 1,674 units of BEAT stock currently worth $3,917.
heartbeam developed a mhealth technology that is diagnostically equivalent to a cardiologist reading a patient’s 12 lead ecg and examining the patient. it comprises a credit card size, 12 lead equivalent, ecg device and a cloud-based diagnostic expert system. studies designed by harvard medical school faculty have shown heartbeam performance to be equal or better than world class cardiologists in diagnosing a heart attack. the technology features personalized diagnostic thresholds and novel heart attack ecg markers from which the application can also help cardiologists locate a heart attack on a 3d model of the heart. heartbeam's icardiologist application utilizes artificial intelligence / machine learning to drive continuous improvements of the system's ability to provide patient analysis and improve the solution's predictive properties.
HeartBeam Inc executives and other stock owners filed with the SEC include: